Telomere-based risk models for the early diagnosis of lung cancer
Year: 2024
Type: article
Study design: Observational Study
Abstract: Background: The objective of this study was to evaluate the use of telomere length measurements as diagnostic biomarkers during early screening for lung cancer in high-risk patients. Methods: This was a prospective study of patients undergoing lung cancer diagnosis at two Spanish hospitals between April 2017 and January 2020. Telomeres from peripheral blood lymphocytes were analysed by Telomere Analysis Technology, which is based in high-throughput quantitative fluorescent in situ hybridization. Analytical predictive models were developed using Random Forest from the dataset of telomere-associated variables (TAV). Receiver Operating Characteristic curves were used to characterize model performance. Findings: From 233 patients undergoing lung cancer diagnosis, 106 patients aged 55-75 with lung cancer or lung cancer and COPD were selected. A control group (N = 453) included individuals of similar age with COPD or healthy. Telomere analysis showed that patients in the cancer cohort had a higher proportion of short telomeres compared to the control cohort. A TAV-based predictive model assuming a prevalence of 5 % of lung cancer among screened subjects showed an AUC of 0.98 %, a positive predictive value of 0.60 (95 % CI, 0.49-0.70) and a negative predictive value of 0.99 (95 % CI, 0.98-0.99) for prediction of lung cancer. Interpretation: The results of this study suggest that TAV analysis in peripheral lymphocytes can be considered a useful diagnostic tool during screening for lung cancer in high-risk patients. TAV-based models could improve the predictive power of current initial diagnostic pathways, but further work is needed to integrate them into routine clinical evaluation. Funding: Life Length SL.
Source: Heliyon
Authors: Sonia Molina-Pinelo, Irene Ferrer Sánchez, Pilar Najarro, Luis Paz-Ares, Luis Fernández, Nila Castelló, Luis Alberto Richart López, Juan Diego Rodríguez Gambarte, Máximo Sanz García, Ana Salinas, Rocío Suárez, Beatriz Romero-Romero, José Martín-Juan, María Eugenia Viñuela, Ray G. Butler, Nuria de Pedro
Institutions: Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Centro de Investigación Biomédica en Red de Cáncer, Universidad de Sevilla, Research Institute Hospital 12 de Octubre, Spanish National Cancer Research Centre, Life Length (Spain), Hospital Universitario 12 De Octubre, Comunidad de Madrid, Hospital Universitario Príncipe de Asturias
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,100
Funders: Comunidad de Madrid, European Commission, Fundación Científica Asociación Española Contra el Cáncer, Federación Española de Enfermedades Raras, Junta de Andalucía, Centro de Investigación Biomédica en Red de Cáncer, Horizon 2020 Framework Programme, HORIZON EUROPE Framework Programme, Instituto de Salud Carlos III
Awards: G1075404386, G1143292233, G1507114846, G2159847587, G3069812683, G4741707801, G4974690386, Personalized multimodal therapies for the treatment of lung cancer, G6102325852, Optimización de la terapia con inhibidores covalentes de KRAS-G12C en el Cáncer de Pulmón No Microcítico (CPNM), A simple blood test for prognosis and monitoring of patients undergoing cancer therapy., Caracterización molecular e inmune del cáncer de pulmón no microcítico (CPNM) como base para la personalización de estrategias de inmunoterapia, Interacción de la interleukina 11 (IL11) con el microambiente tumoral en el adenocarcinoma de pulmón, y estudio de su inhibición como estrategia terapéutica, Caracterización exhaustiva del perfil inmune del cáncer microcítico de pulmón (SCLC): Identificación de nuevas vulnerabilidades terapeúticas y validación funcional, G8718099343, Interferencia epigenética entre las células inmunes y células tumorales de pulmón: potenciales jugadores de la resistencia a la inmunoterapia
OpenAlex ID: W4405109055